EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have shown marked efficacy in non-small cell lung cancer (NSCLC) patients with EGFR mutations [1,2,3,4,5,6].